PURPOSE: @entity400 ( @entity400 ) prolongs progression-free survival 1 (PFS1; time from random assignment until the first progression or @entity204 ), but chemotherapy-resistant relapse may negatively impact @entity1349 ( @entity1349 ). Progression-free survival 2 ( @entity16450 ; time from random assignment until the second progression or @entity204 ) may represent an additional tool to estimate outcome. This study evaluates the benefit of novel agent-based @entity400 versus fixed duration of therapy (FDT) in @entity1 with newly diagnosed @entity1582 . METHODS: We included @entity1 enrolled onto three phase III trials that randomly assigned @entity1 to novel agent-based @entity400 versus FDT. Primary analyses were restricted to the intent-to-treat population eligible for @entity400 ( @entity1 progression free and alive at 1 year after random assignment). Primary end points were PFS1, @entity16450 , and @entity1349 . All hazard ratios (HRs) and 95% CIs were adjusted for several potential confounders using Cox models. RESULTS: In the pooled analysis of the three trials, 604 @entity1 were randomly assigned to @entity400 and 614 were assigned to FDT. Median follow-up was 52 months. In the intent-to-treat @entity400 population, @entity400 (n = 417), compared with FDT (n = 410), significantly improved PFS1 (median, 32 v 16 months, respectively; HR, 0.47; 95% CI, 0.40 to 0.56; P < .001), @entity16450 (median, 55 v 40 months, respectively; HR, 0.61; 95% CI, 0.50 to 0.75; P < .001), and @entity1349 (4-year @entity1349 , 69% v 60%, respectively; HR, 0.69; 95% CI, 0.54 to 0.88; P = .003). CONCLUSION: In this pooled analysis, @entity400 significantly improved PFS1, @entity16450 , and @entity1349 . The improvement in @entity16450 suggests that the benefit reported during first remission is not cancelled by a shorter second remission. @entity16450 is a valuable end point to estimate long-term clinical benefit and should be included in future trials.

Continuous Therapy Versus Fixed Duration of Therapy in XXXX With Newly Diagnosed @entity1582 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity16450 :: ('51659', 'Gene') :: ['PFS2'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['myeloma'] @entity400 :: ('MESH:D014202', 'Disease') :: ['Continuous therapy', 'CT'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1 :: (9606,Species) :: ['Patients']
